ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Bre…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522…

2024 ESMO Annual Meeting Insights Hub

S. Tolaney, H. Rugo

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, …

2024 ESMO Annual Meeting Insights Hub

V. Kaklamani

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

ESMO 2024 Summary: Highlights in mBC

2024 ESMO Annual Meeting Insights Hub

G. Bianchini

NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment i…

Jan-Willem Henning

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

Wassim Mchayleh

ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond

2024 ESMO Annual Meeting Insights Hub

L. Carey

Perspectives on the Effects of Time Toxicity in Breast Cancer Treatm…

Kathryn Post

J. Hutchinson

ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY …

2024 ESMO Annual Meeting Insights Hub

C. Sotiriou